Featured Research

from universities, journals, and other organizations

First Compound For Receptors In Schizophrenia And Alzheimer's Holds Promise

Date:
April 23, 2009
Source:
Federation of American Societies for Experimental Biology
Summary:
Compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease can cause gastrointestinal and other side effects. Thanks to the discovery of a truly selective agonist that targets only the M1 receptor, this may change.

For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease (AD).

Related Articles


But because the compounds are "dirty" – scientific lingo for a lack of selectivity – they activate not only the essential M1 and M 4 muscarinic receptors but also the other three members of the family, designated M2, M3 and M5, resulting in unacceptable gastrointestinal and other side effects.

That may soon change, thanks to the discovery of a truly selective agonist that targets only the M1 receptor, known to be central to cognition and thus implicated in diseases like AD and schizophrenia.

On April 20, speaking at the Experimental Biology 2009 meeting in New Orleans, Vanderbilt graduate student Evan Lebois in the laboratories of Dr. David Weaver and Dr. Craig Lindsley describes the complex, labor-intensive screening and discovery process that allowed Vanderbilt scientists to pinpoint what big pharma's computers and robots could not, and the process now underway to move the compound toward becoming an effective drug to treat AD and schizophrenia. The presentation is part of the scientific program of the American Society for Pharmacology and Experimental Therapeutics.

In stage one, the search for the appropriate molecule, Dr. David Weaver, director of the Vanderbilt Chemical Biology's High-Throughput Screening facility and co-director of the Molecular Library Screening Center, painstakingly ran high-throughput screens of every compound in the molecular library to see which ones activated the M1 receptor. Most such studies are done on computers with robots and automatic scoring mechanisms. By looking with his own eyes at the waveform reactions of every compound in the library, including those already rejected by the robotic systems, Dr. Weaver identified the molecule the scientists dubbed VU019467.

It was now time for stage two, and therefore the turn of Dr. Craig Lindsley, head of Medicinal Chemistry and Director of the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development. His task was to create an effective probe compound.

"There is no point optimizing a molecule's potency in vitro if it turns out not to work in vivo," says Lindsley. His probe works in both. The team now is trying the compound in mouse and rat models of Alzheimer's and schizophrenia to determine what dose range restores the appropriate level of signaling through the targeted receptor. In addition, this compound provides a tool of unprecedented selectivity that will allow the researchers to tease apart the basic role of the M1 and M4 receptors in CNS function and disease states to degree that has never before been possible.

The team hopes that within a year they will have a compound ready to license to a pharmacological company that can continue with preclinical development and then onward to human trials.

Co-authors on the study are Mr. Lebois, who carried out chemical syntheses and conducted the assays; Dr. Weaver and Dr. Lindsley; graduate students Thomas Bridges and Phillip Kennedy; Dr. Zixiu Xiang; Dr. Satyawan Jadhav; Dr. Huiyong Yin; Dr. Carrie Jones; and Dr. Jeffrey Conn, Global Director of the Vanderbilt program in drug discovery. Funding for the research comes from the National institutes of Health, National Institute of Mental Health, and the Molecular Libraries Probe Production Centers Network.


Story Source:

The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.


Cite This Page:

Federation of American Societies for Experimental Biology. "First Compound For Receptors In Schizophrenia And Alzheimer's Holds Promise." ScienceDaily. ScienceDaily, 23 April 2009. <www.sciencedaily.com/releases/2009/04/090420141157.htm>.
Federation of American Societies for Experimental Biology. (2009, April 23). First Compound For Receptors In Schizophrenia And Alzheimer's Holds Promise. ScienceDaily. Retrieved January 30, 2015 from www.sciencedaily.com/releases/2009/04/090420141157.htm
Federation of American Societies for Experimental Biology. "First Compound For Receptors In Schizophrenia And Alzheimer's Holds Promise." ScienceDaily. www.sciencedaily.com/releases/2009/04/090420141157.htm (accessed January 30, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Friday, January 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Binge-Watching TV Linked To Loneliness

Binge-Watching TV Linked To Loneliness

Newsy (Jan. 29, 2015) Researchers at University of Texas at Austin found a link between binge-watching TV shows and feelings of loneliness and depression. Video provided by Newsy
Powered by NewsLook.com
Signs You Might Be The Passive Aggressive Friend

Signs You Might Be The Passive Aggressive Friend

BuzzFeed (Jan. 28, 2015) "No, I&apos;m not mad. Why, are you mad?" Video provided by BuzzFeed
Powered by NewsLook.com
City Divided: A Look at Model Schools in the TDSB

City Divided: A Look at Model Schools in the TDSB

The Toronto Star (Jan. 27, 2015) Model schools are rethinking how they engage with the community to help enhance the lives of the students and their parents. Video provided by The Toronto Star
Powered by NewsLook.com
Man Saves Pennies For 65 Years

Man Saves Pennies For 65 Years

Rooftop Comedy (Jan. 26, 2015) A man in Texas saved every penny he found for 65 years, and this week he finally cashed them in. Bank tellers at Prosperity Bank in Slaton, Texas were shocked when Ira Keys arrived at their bank with over 500 pounds of loose pennies stored in coffee cans. After more than an hour of sorting and counting, it turned out the 81 year-old was in possession of 81,600 pennies, or $816. And he&apos;s got more at home! Video provided by Rooftop Comedy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins